European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024 - Articles - Oncology · Hematology

Genitourinary Cancer

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update

Eur Urol

Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F, Mariappan P, Masson-Lecomte A, Mostafid HA, Pradere B, Rai BP, van Rhijn BWG, Seisen T, Shariat SF, Soria F, Soukup V, Wood R, Xylinas EN

doi: 10.1016/j.eururo.2024.07.027

Lung, Respiratory and Thoracic Cancer

Treatment of Pleural Mesothelioma: ASCO Guideline Update

J Clin Oncol

Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, Dagogo-Jack I, Bryan DS, Drazer MW, Forde P, Husain AN, Sauter JL, Rusch V, Bradbury PA, Cho BCJ, de Perrot M, Ghafoor A, Graham DL, Khorshid O, Lebensohn A, White J, Hassan R

doi: 10.1200/JCO-24-02425

Skin Cancer

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials

J Clin Oncol

Weber JS, Middleton MR, Yates G, Sharpe DJ, Kurt M, Lobo M, Moshyk A, Vanderpuye-Orgle J, Mohr P

doi: 10.1200/JCO.24.00237

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

Head and Neck Cancer

Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw

Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai A, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L

doi: 10.6004/jnccn.2024.0040

SABCS 2024

Breast Cancer

Updates on ADCs in treatment of advanced breast cancer

Further Publications

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin KY, Fogerty AE, Crestani NG, Gangaraju R, Rojas-Hernandez C, Goldhaber SZ, Ibrahim I, Kubal T, Leavitt AD, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel TL, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B

doi: 10.6004/jnccn.2024.0046

Skin Cancer

Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment

J Clin Oncol

Sperduto PW, Marqueen KE, Chang E, Li J, Davies MA, Ebner DK, Breen WG, Lamba N, Shih HA, Edwards D, Kim MM, Mahal A, Rahman R, Ankrah N, Boggs DH, Lewis C, Hyer D, Buatti JM, Johri F, Soliman H, Masucci L, Roberge D, Aneja S, Chiang V, Phuong C, Braunstein S, Dajani S, Sachdev S, Wan Z, Niedzwiecki D, Vaios E, Kirkpatrick JP, Pasetsky J, Wang TJC, Kutuk T, Kotecha R, Ross RB, Rusthoven CG, Nakano T, Tawbi HA, Mehta MP

doi: 10.1200/JCO-24-01351

Nuclear Medicine

[¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Lancet

Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D, all the NETTER-2 Trial Investigators

doi: 10.1016/S0140-6736(24)00701-3

Related content

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update

Treatment of Pleural Mesothelioma: ASCO Guideline Update

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials

Advancing Breast Cancer Treatment with Elacestrant

Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Updates on ADCs in treatment of advanced breast cancer

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

[¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study